TORONTO, ONTARIO–(Marketwire – June 23, 2011) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics (“ACT”) today announced Arch scientists Dr. Donna Senger and Dr. Stephen Robbins have been awarded $561,251 of peer reviewed research funding to support ongoing work in the area of malignant glioma and the development of brain tumour cell targeting technology.
Press Releases
Arch Scientists to Present at ESF-LFUI Conference in Austria
TORONTO, ONTARIO–(Marketwire – May 24, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists Randall Irvin and Elisabeth Davis will be presenting new data at a conference titled “Charge Transfer in Biosystems” sponsored by the European Science Foundation (“ESF”) and University of Innsbruck (“LFUI”) held July 17-22, 2011 at the Universitätszentrum Obergurgl in Tirol, Austria.
Arch Scientists Create New Bio-Organic Metal That Is Harder, Resists Corrosion
TORONTO, ONTARIO–(Marketwire – May 10, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists have reported details of their new technology development at the University of Alberta in the field of biophysics.
Arch Cancer Therapeutics’ Technology Update
TORONTO, ONTARIO–(Marketwire – April 11, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics (“ACT”) today announced Arch scientists have successfully completed proof of principle studies in the area of targeting brain tumour initiating cells.